Edition:
United States

Heat Biologics Inc (HTBX.OQ)

HTBX.OQ on NASDAQ Stock Exchange Capital Market

1.93USD
25 Sep 2018
Change (% chg)

-- (--)
Prev Close
$1.93
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
110,711
52-wk High
$7.85
52-wk Low
$1.09

Chart for

About

Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combinatio... (more)

Overall

Beta: 0.91
Market Cap(Mil.): $44.17
Shares Outstanding(Mil.): 23.13
Dividend: --
Yield (%): --

Financials

  HTBX.OQ Industry Sector
P/E (TTM): -- 109.17 32.55
EPS (TTM): -3.67 -- --
ROI: -92.71 1.47 12.80
ROE: -111.85 0.22 14.92

Heat-stable drug could save thousands from post-childbirth bleeding: WHO

LONDON A new formulation of a drug to prevent excessive bleeding in women after they give birth could save thousands of lives in poorer countries, according to a study co-led by the World Health Organization (WHO).

Jun 27 2018

Heat-stable drug could save thousands from post-childbirth bleeding - WHO

LONDON, June 27 A new formulation of a drug to prevent excessive bleeding in women after they give birth could save thousands of lives in poorer countries, according to a study co-led by the World Health Organization (WHO).

Jun 27 2018

BRIEF-Heat Biologics Inc - QTRLY Loss Per Share $0.75

* HEAT BIOLOGICS INC - QTRLY LOSS PER SHARE $0.75 Source text: (https://bit.ly/2rHWu1b) Further company coverage: (Reuters.Briefs@thomsonreuters.com)

May 15 2018

BRIEF-Heat Biologics Files For Offering Of Up To $15 Mln Of Its Common Stock

* FILES FOR OFFERING OF UP TO $15 MILLION OF ITS COMMON STOCK - SEC FILING Source text for Eikon: (http://bit.ly/2GFwyfW) Further company coverage:

Mar 30 2018

BRIEF-Heat Biologics Reports Data From Phase 2 Trial Of HS-410 Combined With Bacillus Calmette-Guérin For Treating Non-Muscle Invasive Bladder Cancer

* HEAT BIOLOGICS - REPORTS 2 YEAR DATA FROM PHASE 2 TRIAL OF HS-410 COMBINED WITH BACILLUS CALMETTE-GUÉRIN FOR TREATING NON-MUSCLE INVASIVE BLADDER CANCER

Mar 26 2018

Competitors

Earnings vs. Estimates